Danish Business Authority's decision causes Lundbeck to downgrade guidance

Lundbeck adjusts its EBIT guidance after the Danish Business Authority ordered a reassessment of the impairment.
Photo: Martin Lehmann/Ritzau Scanpix
Photo: Martin Lehmann/Ritzau Scanpix
BY JULIE FOGDE, TRANSLATED BY NIELSINE NIELSEN

Now, the Danish pharmaceutical firm Lundbeck's operational guidance for 2020 is at DKK 1.7-1.9bn (USD 275.6m-308.0m), down from DKK 2.0-2.2n. Lundbeck, however, states that its guidance for earnings before interest, taxes, depreciations and amortizations and core EBIT remain unchanged, according to a stock exchange announcement on Friday afternoon.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
!
!
Must contain at least 6 characters
!
Must contain at least 2 characters
!
Must contain at least 2 characters

Get full access for you and your coworkers

Start a free company trial today

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

!
Newsletter terms

Front page now

Further reading